Navigation Links
Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
Date:7/18/2011

colitis and for the maintenance of remission of ulcerative colitis. Lialda is available as a delayed-release tablet containing 1.2 g mesalamine. For the induction of remission in patients with active, mild to moderate ulcerative colitis, the recommended dosage is two or four 1.2 g tablets taken once daily with a meal. The recommended dosage for the maintenance of remission of ulcerative colitis is two 1.2 g tablets taken once daily with a meal.


About Ulcerative Colitis


Ulcerative colitis is a type of inflammatory disease. It only affects the colon, producing chronic inflammation and sometimes sores or ulcers along the inside lining of the colon. It is characterized by diarrhea, which is generally bloody, and often painful cramping in the abdomen. Currently, there is no cure available with medical treatment, and the cause of the disease is unknown.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not hi
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire plc : Second Quarter 2011 Results Date Notification - July 28, 2011
2. Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents
3. United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk
4. Shire Completes Acquisition of Advanced BioHealing, Inc.
5. European Authorities Approve New Manufacturing Facility for Shires REPLAGAL® (agalsidase alfa)
6. Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
7. Shire Recognized by ISPE Facility of the Year Awards Program
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
10. Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
11. Atrium Recognized by New Hampshire Bio/Medical Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... GRONINGEN, Netherlands , July 26 ... organization providing testing services to support preclinical and clinical ... of Xendo Drug Development BV (XDD), headquartered in Groningen, ... organization (CRO), will be known as QPS Netherlands BV ...
... Harco Metal Products (Harco), an industry leader in tube ... contract to manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products ... risk and cost associated with staff injuries caused by physically lifting ...
Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
(Date:11/27/2014)... 2014 "The uglier, the better," says Dr. ... is full of laughter as we enjoy the ugly sweater ... a sweater from scratch. " It was a sight to ... that weren't ridiculous enough, the Christmas balls were faces of ... those interested in participating this year, it's simple to get ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... to a hundred years ago are being used in the ... the first time old bones have been used in this ... combination of latest computer modelling techniques developed at the University ... of Bristol. With Engineering and Physical Sciences Research Council ...
... core professional obligation and lying, even for a patient, ... Jr., MD, FACP, president of the American College of ... internal medicine physician and medical student members today. ... "sick notes" issued without a medical evaluation to some ...
... HealthDay Reporter , MONDAY, Feb. 28 (HealthDay News) ... in which inflammation of the lining of the nose and ... the most severe cases, patients develop nasal polyps that can ... to begin with a steroid nasal spray and then move ...
... , MONDAY, Feb. 28 (HealthDay News) -- Few things send ... rising temperature. But, a new report from the American ... reminding parents that a fever is usually just the body,s ... actually prolong an illness. The AAP recommends that, in ...
... , MONDAY, Feb. 28 (HealthDay News) -- Heart ... positive outlook, researchers are reporting. More than 2,800 heart ... their belief in their ability to recover from the illness ... 1,637 of the patients had died. Of those deaths, 885 ...
... MONDAY, Feb. 28 (HealthDay News) -- The stress of ... and gain weight, researchers report. The Georgia Health ... 60 first-time mothers who were asked about their levels ... a low amount of physical activity, was most influenced ...
Cached Medicine News:Health News:Learning from old bones to treat modern back pain 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 2Health News:For Severe Sinusitis, Oral Steroids an Option, Study Says 3Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Stress May Help Spur Weight Gain in New Moms, Study Finds 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: